Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
- Details
- Category: Novartis
Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.
Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE technology
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology.
More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
- Details
- Category: Novo Nordisk
A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER).
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab
- Details
- Category: AstraZeneca
AstraZeneca has announced results from a subgroup analysis of the SIROCCO and CALIMA Phase III trials. The results confirm benralizumab's compelling efficacy and identify key factors that predict which patients with severe, uncontrolled asthma would respond best to treatment with this potential new medicine.
Merck set to join forces with Project Data Sphere to pioneer Global Oncology Big Data Alliance
- Details
- Category: Merck Group
Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium, to jointly lead the Global Oncology Big Data Alliance (GOBDA).
Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy designation for advanced cutaneous squamous cell carcinoma
- Details
- Category: Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma[1], [2]. Cemiplimab is an investigational human, monoclonal antibody targeting PD-1.
Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in immuno-oncology
- Details
- Category: Merck
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Rigontec announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity.
More Pharma News ...
- Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics
- Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
- Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer
- Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®
- Abbott and the Abbott Fund donate $1 million to support Hurricane Harvey relief efforts
- Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019)
- Merck collaborates with angiex to speed clinical readiness of new cancer therapy